Your browser doesn't support javascript.
ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge.
Fischer, Robert J; Purushotham, Jyothi N; van Doremalen, Neeltje; Sebastian, Sarah; Meade-White, Kimberly; Cordova, Kathleen; Letko, Michael; Jeremiah Matson, M; Feldmann, Friederike; Haddock, Elaine; LaCasse, Rachel; Saturday, Greg; Lambe, Teresa; Gilbert, Sarah C; Munster, Vincent J.
  • Fischer RJ; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
  • Purushotham JN; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
  • van Doremalen N; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Sebastian S; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
  • Meade-White K; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Cordova K; Vaccitech Limited, Oxford, UK.
  • Letko M; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
  • Jeremiah Matson M; Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
  • Feldmann F; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
  • Haddock E; Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA, USA.
  • LaCasse R; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
  • Saturday G; Marshall University Joan C. Edwards School of Medicine, Huntington, WV, USA.
  • Lambe T; Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
  • Gilbert SC; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
  • Munster VJ; Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
NPJ Vaccines ; 6(1): 32, 2021 Mar 02.
Article in English | MEDLINE | ID: covidwho-1146187
ABSTRACT
Lassa virus (LASV) infects hundreds of thousands of individuals each year, highlighting the need for the accelerated development of preventive, diagnostic, and therapeutic interventions. To date, no vaccine has been licensed for LASV. ChAdOx1-Lassa-GPC is a chimpanzee adenovirus-vectored vaccine encoding the Josiah strain LASV glycoprotein precursor (GPC) gene. In the following study, we show that ChAdOx1-Lassa-GPC is immunogenic, inducing robust T-cell and antibody responses in mice. Furthermore, a single dose of ChAdOx1-Lassa-GPC fully protects Hartley guinea pigs against morbidity and mortality following lethal challenge with a guinea pig-adapted LASV (strain Josiah). By contrast, control vaccinated animals reached euthanasia criteria 10-12 days after infection. Limited amounts of LASV RNA were detected in the tissues of vaccinated animals. Viable LASV was detected in only one animal receiving a single dose of the vaccine. A prime-boost regimen of ChAdOx1-Lassa-GPC in guinea pigs significantly increased antigen-specific antibody titers and cleared viable LASV from the tissues. These data support further development of ChAdOx1-Lassa-GPC and testing in non-human primate models of infection.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2021 Document Type: Article Affiliation country: S41541-021-00291-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2021 Document Type: Article Affiliation country: S41541-021-00291-x